Fentanyl buccal - BioDelivery Sciences

Drug Profile

Fentanyl buccal - BioDelivery Sciences

Alternative Names: BEMA-Fentanyl; Breakyl; Fentanyl buccal soluble film; Fentanyl transmucosal - BioDelivery Sciences; Onsolis; Painkyl

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator QLT USA
  • Developer BioDelivery Sciences International; Meda; TTY Biopharm
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Cancer pain

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 11 May 2016 Buccal fentanyl licensed to Collegium Pharmaceutical in USA
  • 07 Apr 2015 No recent reports of development identified - Preregistration for Cancer pain in Australia (Buccal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top